Document is current
Any future updates will be listed below
-
Authors
Ryan, Paul M.
Stolte, Ellen H.
London, Lis E. E.
Wells, Jerry M.
Long, Sarah L.
Joyce, Susan A.
Gahan, Cormac G. M.
Fitzgerald, Gerald F.
Ross, R. Paul
Caplice, Noel M.
Stanton, Catherine
-
Funding
Funding for this research was provided by:
Science Foundation Ireland (SFI/12/RC/2273)
Enterprise Ireland (CF/2013/3030A/B)
FP7 Research for the Benefit of SMEs (289517)
- License Information
-
More Information
Article History
Received: 20 May 2018
Accepted: 28 January 2019
First Online: 8 February 2019
Ethics approval and consent to participate
: For experiments involving isolated human neutrophils, written informed consent was obtained from study participants in line with institutional and national clinical research regulations. Blood was drawn solely for the purpose of the outlined experiments and not for medical purposes. Ethical approval for donations and experiments was obtained from the Wageningen local ethical board (No. NL.44545.091.13).
: Not applicable.
: NMC, CS, RPR and GFF hold a patent for the cardio-protective attributes of the microbial strain reported in this study: patent number US9808493B2, “<i>Exopolysaccharide-producing bacteria, and uses thereof for protecting heart health</i>”. The remaining authors have no duality of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
